This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Histologically confirmed advanced or metastatic pleural mesothelioma;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have previously failed to receive platinum-containing chemotherapy with or without bevacizumab, and have received at most two-line systemic therapy.
Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
Primary mesothelioma of peritoneum, pericardium and testes
Active, untreated central nervous system (CNS) metastasis.
Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
Known active autoimmune diseases.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead sponsor
Akesobio
Collaborator